MOH · Molina Healthcare, Inc.

The shares were applied to the payment of withholding taxes arising in connection with the vesting of 529 shares on July 1, 2026.

The shares vest as follows: 4,977 shares on March 1, 2027; 4,220 shares on March 1, 2028; and 3,202 shares on March 1, 2029. The remaining shares are vested.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on July 1, 2026 was $232.55, which resulted in a grant of 237 shares.

Represents the closing price of the Issuer's common stock on July 1, 2026.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on July 1, 2026 was $232.55, which resulted in a grant of 237 shares.

Represents the closing price of the Issuer's common stock on July 1, 2026.

All shares held by Ronna Romney Revocable Trust.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on July 1, 2026 was $232.55, which resulted in a grant of 237 shares.

Represents the closing price of the Issuer's common stock on July 1, 2026.

All shares held by the Richard Charles Zoretic Revocable Living Trust.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on July 1, 2026 was $232.55, which resulted in a grant of 237 shares.

Represents the closing price of the Issuer's common stock on July 1, 2026.

Shares are held by Orlando Family Trust.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on July 1, 2026 was $232.55, which resulted in a grant of 237 shares.

Represents the closing price of the Issuer's common stock on July 1, 2026.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on July 1, 2026 was $232.55, which resulted in a grant of 237 shares.

Represents the closing price of the Issuer's common stock on July 1, 2026.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on July 1, 2026 was $232.55, which resulted in a grant of 237 shares.

Represents the closing price of the Issuer's common stock on July 1, 2026.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on July 1, 2026 was $232.55, which resulted in a grant of 237 shares.

Represents the closing price of the Issuer's common stock on July 1, 2026.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on July 1, 2026 was $232.55, which resulted in a grant of 237 shares.

Represents the closing price of the Issuer's common stock on July 1, 2026.

Shares are held by Dale B. Wolf Revocable Trust, of which Dale B. Wolf is the sole trustee.

The shares were acquired under the Molina Healthcare, Inc. 2019 Employee Stock Purchase Plan (the "ESPP").

In accordance with the ESPP, the purchase price is 85% of the closing price of the Issuer's common stock on January 1, 2026 of $173.54 (which represents the lower market price of the Issuer's common stock as of (i) January 1, 2026, the first date of the ESPP offering period, and (ii) June 30, 2026, the last trading day of the offering period).

The shares vest as follows: 9,304 shares on March 1, 2027; 7,754 shares on March 1, 2028; and 5,672 shares on March 1, 2029. The remaining shares are vested.

The shares were acquired under the Molina Healthcare, Inc. 2019 Employee Stock Purchase Plan (the "ESPP").

In accordance with the ESPP, the purchase price is 85% of the closing price of the Issuer's common stock on January 1, 2026 of $173.54 (which represents the lower market price of the Issuer's common stock as of (i) January 1, 2026, the first date of the ESPP offering period, and (ii) June 30, 2026, the last trading day of the offering period).

The shares were acquired under the Molina Healthcare, Inc. 2019 Employee Stock Purchase Plan (the "ESPP").

In accordance with the ESPP, the purchase price is 85% of the closing price of the Issuer's common stock on January 1, 2026 of $173.54 (which represents the lower market price of the Issuer's common stock as of (i) January 1, 2026, the first date of the ESPP offering period, and (ii) June 30, 2026, the last trading day of the offering period).

The shares vest as follows: 7,296 shares on March 1, 2027; 6,193 shares on March 1, 2028; and 4,574 shares on March 1, 2029. The remaining shares are vested.

Represents the selling price per share of all 600 shares.

The shares vest as follows: 1,245 shares on March 1, 2027; 986 shares on March 1, 2028, and 686 shares on March 1, 2029. The remaining shares are vested.

Price is the volume weighted average selling price of all sales by the Reporting Person on the transaction date within a one-dollar range. Actual prices ranged from $186.01 to $186.86. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

The shares vest as follows: 7,296 shares on March 1, 2027; 6,193 shares on March 1, 2028; and 4,574 shares on March 1, 2029. The remaining shares are vested.

Grant of stock under the Issuer's 2025 Incentive Plan in connection with the Reporting Person's services as a Director.

Represents the prorated quarterly director grant. Mr. Soistman was elected as a director on May 6, 2026.

Represents the closing price of the Issuer's common stock on May 6, 2026.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on April 1, 2026 was $135.82, which resulted in a grant of 405 shares.

Represents the closing price of the Issuer's common stock on April 1, 2026.

All shares held by the Richard Charles Zoretic Revocable Living Trust.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on April 1, 2026 was $135.82, which resulted in a grant of 405 shares.

Represents the closing price of the Issuer's common stock on April 1, 2026.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on April 1, 2026 was $135.82, which resulted in a grant of 405 shares.

Represents the closing price of the Issuer's common stock on April 1, 2026.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on April 1, 2026 was $135.82, which resulted in a grant of 405 shares.

Represents the closing price of the Issuer's common stock on April 1, 2026.

Shares are held by Orlando Family Trust.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on April 1, 2026 was $135.82, which resulted in a grant of 405 shares.

Represents the closing price of the Issuer's common stock on April 1, 2026.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on April 1, 2026 was $135.82, which resulted in a grant of 405 shares.

Represents the closing price of the Issuer's common stock on April 1, 2026.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on April 1, 2026 was $135.82, which resulted in a grant of 405 shares.

Represents the closing price of the Issuer's common stock on April 1, 2026.

Shares are held by Dale B. Wolf Revocable Trust, of which Dale B. Wolf is the sole trustee.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on April 1, 2026 was $135.82, which resulted in a grant of 405 shares.

Represents the closing price of the Issuer's common stock on April 1, 2026.

All shares held by Ronna Romney Revocable Trust.

Price is the volume weighted average selling price of all sales by the Reporting Person on the transaction date within a one-dollar range. Actual prices ranged from $146.80 to $147.10. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

All shares held by Ronna Romney Revocable Trust.

The shares were applied to the payment of withholding taxes arising in connection with the vesting of 5,337 shares on March 1, 2026.

Represents the closing price of the Issuer's common stock on February 27, 2026.

The shares were applied to payment of withholding taxes in connection with vesting of the above-mentioned performance stock units.

Represents the closing price of the Issuer's common stock on February 27, 2026.

Grant of restricted stock under the Issuer's 2025 Equity Incentive Plan.

Represents the volume-weighted average price (VWAP) of the Company's common stock for the ten (10) trading dates immediately preceding the March 1, 2026 grant date.

The shares shall vest as follows: The 9,606 newly granted shares shall vest in one-third increments on each of March 1, 2027, March 1, 2028, and March 1, 2029. Additional shares shall vest as follows: 529 shares on July 1, 2026; 1,775 shares on March 1, 2027; and 1,018 on March 1, 2028. The remaining shares are vested.

The shares were applied to the payment of withholding taxes arising in connection with the vesting of 20,623 shares on March 1, 2026.

Represents the closing price of the Issuer's common stock on February 27, 2026.

Grant of restricted stock under the Issuer's 2025 Equity Incentive Plan.

Represents the volume-weighted average price (VWAP) of the Company's common stock for the ten (10) trading dates immediately preceding the March 1, 2026 grant date.

The shares shall vest as follows: The 2,058 newly granted shares shall vest in one-third increments on each of March 1, 2027, March 1, 2028, and March 1, 2029. Additional shares shall vest as follows: 559 shares on March 1, 2027; and 300 shares on March 1, 2028. The remaining shares are vested.

The shares were applied to the payment of withholding taxes arising in connection with the vesting of 4,183 shares on March 1, 2026.

Represents the closing price of the Issuer's common stock on February 27, 2026.

Grant of restricted stock under the Issuer's 2025 Equity Incentive Plan.

Represents the volume-weighted average price (VWAP) of the Company's common stock for the ten (10) trading dates immediately preceding the March 1, 2026 grant date.

The shares shall vest as follows: The 17,016 newly granted shares shall vest in one-third increments on each of March 1, 2027, March 1, 2028, and March 1, 2029. Additional shares shall vest as follows: 3,632 shares on March 1, 2027; and 2,082 shares on March 1, 2028. The remaining shares are vested.

The shares were applied to the payment of withholding taxes arising in connection with the vesting of 802 shares on March 1, 2026.

Represents the closing price of the Issuer's common stock on February 27, 2026.

Grant of restricted stock under the Issuer's 2025 Equity Incentive Plan.

Represents the volume-weighted average price (VWAP) of the Company's common stock for the ten (10) trading dates immediately preceding the March 1, 2026 grant date.

The shares shall vest as follows: The 66,417 newly granted shares shall vest in one-third increments on each of March 1, 2027, March 1, 2028, and March 1, 2029. Additional shares shall vest as follows: 13,075 shares on March 1, 2027; and 7,497 shares on March 1, 2028. The remaining shares are vested.

Shares issued in settlement of performance stock units granted on March 1, 2023, based on the Company's achievement of three-year average adjusted earnings per share, at 89% vesting level.

Represents the closing price of the Issuer's common stock on February 27, 2026.

Grant of restricted stock under the Issuer's 2025 Equity Incentive Plan.

Represents the volume-weighted average price (VWAP) of the Company's common stock for the ten (10) trading dates immediately preceding the March 1, 2026 grant date.

The shares shall vest as follows: The 13,722 newly granted shares shall vest in one-third increments on each of March 1, 2027, March 1, 2028, and March 1, 2029. Additional shares shall vest as follows: 2,722 shares on March 1, 2027; and 1,619 shares on March 1, 2028. The remaining shares are vested.

The shares were applied to the payment of withholding taxes arising in connection with the vesting of 6,563 shares on March 1, 2026.

Represents the closing price of the Issuer's common stock on February 27, 2026.

Grant of restricted stock under the Issuer's 2025 Equity Incentive Plan.

Represents the volume-weighted average price (VWAP) of the Company's common stock for the ten (10) trading dates immediately preceding the March 1, 2026 grant date.

The shares shall vest as follows: The 26,073 newly granted shares shall vest in one-third increments on each of March 1, 2027, March 1, 2028, and March 1, 2029. Additional shares shall vest as follows: 4,613 shares on March 1, 2027; and 2,892 shares on March 1, 2028. The remaining shares are vested.

The shares were applied to the payment of withholding taxes arising in connection with the vesting of 2,021 shares on March 1, 2026.

Represents the closing price of the Issuer's common stock on February 27, 2026.

All shares held by the Richard Charles Zoretic Revocable Living Trust.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. Since the grant date of January 1, 2026, was a non-trading day, the number of shares was calculated based on the closing price of the Issuer's common stock on December 31, 2025, of $173.54. Thus, the grant this quarter for services as a Director is for 317 shares of the Issuer's common stock.

Represents the closing price of the Issuer's common stock on December 31, 2025.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. Since the grant date of January 1, 2026, was a non-trading day, the number of shares was calculated based on the closing price of the Issuer's common stock on December 31, 2025, of $173.54. Thus, the grant this quarter for services as a Director is for 317 shares of the Issuer's common stock.

Represents the closing price of the Issuer's common stock on December 31, 2025.

Shares are held by Dale B. Wolf Revocable Trust, of which Dale B. Wolf is the sole trustee.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. Since the grant date of January 1, 2026, was a non-trading day, the number of shares was calculated based on the closing price of the Issuer's common stock on December 31, 2025, of $173.54. Thus, the grant this quarter for services as a Director is for 317 shares of the Issuer's common stock.

Represents the closing price of the Issuer's common stock on December 31, 2025.

Shares are held by Orlando Family Trust.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. Since the grant date of January 1, 2026, was a non-trading day, the number of shares was calculated based on the closing price of the Issuer's common stock on December 31, 2025, of $173.54. Thus, the grant this quarter for services as a Director is for 317 shares of the Issuer's common stock.

Represents the closing price of the Issuer's common stock on December 31, 2025.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. Since the grant date of January 1, 2026, was a non-trading day, the number of shares was calculated based on the closing price of the Issuer's common stock on December 31, 2025, of $173.54. Thus, the grant this quarter for services as a Director is for 317 shares of the Issuer's common stock.

Represents the closing price of the Issuer's common stock on December 31, 2025.

All shares held by Ronna Romney Revocable Trust.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. Since the grant date of January 1, 2026, was a non-trading day, the number of shares was calculated based on the closing price of the Issuer's common stock on December 31, 2025, of $173.54. Thus, the grant this quarter for services as a Director is for 317 shares of the Issuer's common stock.

Represents the closing price of the Issuer's common stock on December 31, 2025.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. Since the grant date of January 1, 2026, was a non-trading day, the number of shares was calculated based on the closing price of the Issuer's common stock on December 31, 2025, of $173.54. Thus, the grant this quarter for services as a Director is for 317 shares of the Issuer's common stock.

Represents the closing price of the Issuer's common stock on December 31, 2025.

Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. Since the grant date of January 1, 2026, was a non-trading day, the number of shares was calculated based on the closing price of the Issuer's common stock on December 31, 2025, of $173.54. Thus, the grant this quarter for services as a Director is for 317 shares of the Issuer's common stock.

Represents the closing price of the Issuer's common stock on December 31, 2025.

All shares held by the Richard Charles Zoretic Revocable Living Trust.

The shares were acquired under the Molina Healthcare, Inc. 2019 Employee Stock Purchase Plan (the "ESPP").

In accordance with the ESPP provisions, the purchase price of $147.51 is 85% of $173.54 which was the closing price of the Issuer's common stock on December 31, 2025, the last trading day of the ESPP offering period. The purchase price is based on the lower market price as of the two following dates: (i) July 1, 2025, the first day of the ESPP offering period, and (ii) December 31, 2025, the last day of the ESPP offering period.

The shares vest as follows: 2,021 shares on March 1, 2026; 529 shares on July 1, 2026; 1,775 shares on March 1, 2027; and 1,018 shares on March 1, 2028. The remaining shares are vested.

Price is the volume weighted average selling price of all sales by the Reporting Person on the transaction date within a one-dollar range. Actual prices ranged from $143.00 to $143.18. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.